Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as GBX 0.87 ($0.01) and last traded at GBX 0.98 ($0.01), with a volume of 16328066 shares traded. The stock had previously closed at GBX 0.93 ($0.01).
Hemogenyx Pharmaceuticals Trading Up 6.5 %
The company has a current ratio of 4.38, a quick ratio of 6.72 and a debt-to-equity ratio of 92.09. The stock has a market capitalization of £15.28 million, a price-to-earnings ratio of -114.00 and a beta of 3.14. The business has a 50 day simple moving average of GBX 1.34 and a 200-day simple moving average of GBX 1.36.
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Featured Stories
- Five stocks we like better than Hemogenyx Pharmaceuticals
- What Does a Stock Split Mean?
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- What Are Dividend Contenders? Investing in Dividend Contenders
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
